Next-generation therapies now.
Is your facility ready for tomorrow’s opportunities?
As cell and gene therapy technology rapidly advances, your challenge is not just keeping up—it’s anticipating what’s coming next. It’s implementing novel processes with facility and technology structures unlike anything we’ve seen. It’s mitigating the risk involved with producing life-altering complex therapies. It’s leading the way and defining the future.
How can CRB help you?
Visionary biotech leaders in need of state-of-the-art CGMP research and manufacturing facilities turn to CRB for our design, construction and process expertise. In an all-new and unpredictable market, trust that your success is built on what we’ve learned from the front lines of advanced therapy medicinal product (ATMP) production. This is complemented by engineering expertise that can reduce your overhead costs, identify opportunities to expand your pipeline, and help you to navigate the complexities of a transitional regulatory landscape.
“With CRB, we achieved the impossible. In just 15 months, they helped us design and build a 75,000-square-foot state-of-the-art bioservice facility, which now supports over 40 clinical programs. It’s not just the speed that’s remarkable. It’s the vision that CRB brought to the project. They conquered every challenge with innovation and skill.”
-Chris Holmes, VP Facilities & Engineering, Paragon Bioservices
Together, let’s create a solution that uses the best technology and the most advanced processes in the world to meet the urgent needs of critically ill patients and their families.
Tell us more about your project.
What we do:
Seamlessly adopt new processes and produce higher quality therapeutics faster.
Stay ahead of the rapidly evolving biotech industry with a flexible facility and expertly designed process systems. You’ll be positioned to readily adapt to new advances while producing the best quality drug products quickly and cost-effectively.Read More
Introducing Horizons, a new CRB insights series exploring key trends across the life sciences.
Our new report explores how cell and gene therapy companies are meeting the obstacles and opportunities of a world on defense against disease.